Alzheimer's-focused Celdara Medical High-Potential Entrepreneurial Fellowship Program (A-CHEF)

专注于阿尔茨海默病的 Celdara 医疗高潜力创业奖学金计划 (A-CHEF)

• 批准号: 10675010
• 负责人: Julie H Coleman
• 金额: $ 16.2万
• 依托单位: CELDARA MEDICAL, LLC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-01 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10675010
• 关键词: Academia; Active Learning; Aducanumab; Advisory Committees; Alzheimer' s Disease; Alzheimer' s disease therapeutic; Award; Biological; Biotechnology; COVID-19 pandemic; Clinic; Clinical; Collaborations; Communication; Development; Development Plans; Diagnosis; Disease; Doctor of Philosophy; Education; Educational Curriculum; Entrepreneurship; Evaluation; Feedback; Fellowship; Fellowship Program; Funding; Grant; Immersion; Individual; Intellectual Property; Intelligence; Laboratories; Leadership; Learning; Maine; Medical; Medical center; Mentors; Mentorship; Names; National Institute of General Medical Sciences; Outcome; Patients; Persons; Phase; Pilot Projects; Preparation; Process; Research; Running; Scientist; Small Business Innovation Research Grant; Structure; Therapeutic; Training; Training Programs; Universities; Writing; apprenticeship; biomedical scientist; career; career development; cognitive function; college; coronavirus disease; drug development; effective therapy; flexibility; improved; innovation; lens; next generation; novel; operation; pre-clinical; preclinical development; programs; recruit; responsible research conduct; success; therapeutic development

While the majority of biomedical scientists end up in professions outside of academia, most receive little-to-no training in preparation for this transition. Here, we seek to establish a comprehensive training program to prepare scientists for their actual careers: to meet the nation’s greatest biomedical and clinical needs. This program includes a core curriculum covering key aspects of drug development (e.g., due diligence, preclinical development, clinical unmet need, intellectual property management, regulatory path, financing, competitive intelligence, and scientific communication), experiential learning, regular, structured collaboration with biotech professionals, training in SBIR grant mechanisms and writing, engagement with multiple early-stage biotech companies, a complementary online training platform, and a formal mentoring program. This program will be focused on one of the most critical disease-challenges of the 21st century: Alzheimer’s Disease (AD) and is named the Alzheimer’s-focused Celdara Medical High-Potential Entrepreneurs’ Fellowship (A-CHEF). Celdara Medical (CM) is an entrepreneurial biotech company that builds academic innovations into high-potential therapeutics. A-CHEF will be run by CM in collaboration with eight universities: Brown, Dartmouth, Maine Medical Center, MDI Biological Laboratory, UDel, UNH, URI, and UVM. CM currently collaborates with each of these universities through its leadership of the NIGMS-funded Regional Accelerator Hub, the DRIVEN Accelerator Hub. CM has previously run a fellowship program (Celdara fellowship) in collaboration with Dartmouth College that acts as a pilot study for A-CHEF. The Celdara fellowship provides evidence of success, as well as a basic training structure to formalize, expand, and improve upon. A-CHEF Annual Milestones: 1) Train ≥ 5 diverse scientists from the Northeast IDeA states each year in biomedical entrepreneurship / drug development; each Fellow will (annually): a) Complete A-CHEF didactic training b) Complete due diligence on ≥ 30 AD-relevant therapeutics; c) Prepare at least one AD therapeutic pitch and present to the CM and DRIVEN teams; d) Create and iterate upon an adaptive individual development plan (IDP). 2) Create a complete funding and development plan (preclinical to clinical) for ≥1 AD therapeutic. Successful completion of the aims and milestones outlined in this application will provide invaluable immersive training and career development for biomedical scientists while also expanding the AD research workforce and advancing AD therapeutic development.

虽然大多数生物医学科学家最终都来自学术界以外的职业，但大多数人几乎没有接受这项过渡的准备。在这里，我们试图建立一项全面的培训计划，以准备科学家的实际职业：满足美国最大的生物医学和临床需求。该课程包括一项核心课程，涵盖了药物开发的关键方面（例如，尽职调查，临床前开发，未满足的需求，知识产权管理，监管路径，融资，竞争性智力和科学交流），经验丰富的学习，定期学习，与生物技术专业人员的固定，结构化的合作，在生物技术方面进行培训，从事sbir授予机制的培训和培训正式的培训培训，与多个现年培训培训多个阶段，培训多个阶段的生物，并培训多个阶段，一家培训，一家完整的生物，一家完整的培训，一家完整的培训。该计划将集中于21世纪最关键的疾病挑战者之一：阿尔茨海默氏病（AD），是 被任命为以阿尔茨海默氏症为重点的Celdara Medical高潜力企业家奖学金（A-CHEF）。 Celdara Medical（CM）是一家企业家生物技术公司，将学术创新建立为高电势疗法。 A-CHEF将由CM与八所大学合作运营：布朗，达特茅斯，缅因州医疗中心，MDI生物实验室，Udel，UNH，UNH，URI和UVM。 CM目前通过其领导NIGMS资助的区域加速器枢纽（驱动的加速器中心）的领导才能与这些大学合作。 CM此前曾与达特茅斯学院合作开展了奖学金计划（Celdara奖学金），该学院是A-CHEF的试点研究。 Celdara奖学金提供了成功的证据，以及正式扩大，扩展和改进的基本培训结构。 A-CHEF年度里程碑：1）每年在生物医学企业家 /药物开发中，来自东北思想状态的5个潜水员科学家；每个研究员（每年）将：a）完成A-CHEF教学训练b）≥30次相关治疗的尽职调查； c）至少准备一个广告治疗螺距，并向CM和驱动的团队展示； d）创建并迭代自适应个人发展计划（IDP）。 2）制定一个完整的资金和开发计划（临床上的临床前），以进行≥1个AD疗法。成功完成本申请中概述的目标和里程碑将为生物医学科学家提供宝贵的沉浸式培训和职业发展，同时还扩大了广告研究人员的发展并推进了广告疗法的发展。